IP Library › Granted Patent US 12,378,550
Granted Patent B2
US 12,378,550 · App. 17/121,835 · Granted Aug 5, 2025

Compositions and methods for nucleic acid transfer

Inventors: Assem G. Ziady (Newport, KY); Matthew Siefert (Cincinnati, OH); Songbai Lin (Lawrenceville, GA); Harrison Brown (Atlanta, GA)
Assignee: Children's Hospital Medical Center
C12N15/113A61K31/05A61K31/132A61K31/265A61K31/352A61K31/395A61K31/4709A61K31/519A61K31/52A61K31/565A61K31/573A61K31/704A61K31/7048A61K31/7088A61K31/713A61K38/1709A61K45/06A61K47/60A61K47/6455A61K48/0008A61K48/0066C12N15/111C12N15/85A61K35/28C12N2310/14C12N2320/31C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,550
App. No.
17/121,835
Granted
Aug 5, 2025
Kind
B2
Abstract

Disclosed are methods for the enhancement of nucleic acid delivery systems. The methods may employ treatment with a compound and/or an RNAi molecule in combination with a nucleic acid to improve nucleic acid uptake into a cell. In particular, the disclosed methods may be useful for improved gene therapy techniques.

Claims (20)

1. A method for transferring a nucleic acid comprising a gene of interest into a eukaryotic cell, comprising

a. contacting said eukaryotic cell with an active agent selected from one or more of geldanamycin, alvespimycin, androstanolone, spermine, cortisone, quercetin, acetohexamide, resveratrol, doxorubicin, ruxolitinib, roscovitine, sildenafil, entasobulin, memantine, teniposide, etoposide, 3-aminobenzamide (INO 1001), diazoxide, tedisamil, glimepiride, epirubicin, annamycin, As 2 O 3 , (R/S)-repaglinide, 4β-aminoalkyl-4′-O-demethyl-4-desoxypodophyllotoxin (TOP53), acetohexamide, elasmitrucin, ketamine, NK109, tifenazoxide, olaparib, and intoplicine, in an amount sufficient to inhibit synthesis of one or more proteins that inhibit nucleic acid delivery vehicle uptake; and

b. contacting said eukaryotic cell with a nucleic acid nanoparticle; said nucleic acid nanoparticle comprising a polymer of lysine conjugated to PEG and complexed with said nucleic acid.

2. The method of claim 1 , further comprising contacting said eukaryotic cell with an RNAi molecule that inhibits expression of a gene encoding a protein selected from Apolipoprotein B-100 (Apo B-100), Leiomodin-1, Elongation factor 1-alpha 1, Pot. HLA-DP-alpha 1, Utrophin, Myosin light chain 3, Cytochrome b-c1 complex subunit 2, Ubiquitin-conjugating enzyme E2 S, Coagulation factor VIII, Heterogeneous nuclear ribonucleoprotein M, Myosin light polypeptide 6, Adenomatous polyposis coli protein, Tyrosine-protein kinase JAK1, Myosin-6, 40S ribosomal protein S3a, Golgin subfamily A member 2, Peripherin (Neurofilament 4), Heterogeneous nuclear ribonucleoprotein A/B, Spectrin beta chain, erythrocytic, Dual specificity protein kinase TTK, 78 kDa glucose-regulated protein, CACCC box-binding protein, 60S ribosomal protein L11, Eukaryotic initiation factor 4A-III, Interleukin enhancer-binding factor 2, Nucleolar and coiled-body phosphoprotein 1, Nebulin, Microtubule-associated protein, DNA replication licensing factor MCM4, Centromere protein F (CENP-F), Cytoskeleton-associated protein 5, Chromodomain-helicase-DNA-binding protein 4, Solute carrier family 12 member 3, Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1, Periodic tryptophan protein 2 homolog, DNA mismatch repair protein Msh3, Ubiquitin-protein ligase E3A, SWI/SNF complex subunit SMARCC1, Histone H2B type 1-C/E/F/G/I, Histone-lysine N-methyltransferase EZH1, Endonuclease III-like protein 1, General transcription factor 3C polypeptide 1, Histone-lysine N-methyltransferase 2D (Lysine N-methyltransferase 2D), Uracil nucleotide/cysteinyl leukotriene receptor, Catenin delta-2, Heme oxygenase 2, Periplakin, Ryanodine receptor 3, Cullin-3, Small subunit processome component 20 homolog, T13D8.9 protein, RNA-binding motif protein, X chromosome, Protein CBFA2T3, Peripheral-type benzodiazepine receptor-associated protein 1, Actin, gamma-enteric smooth muscle, Regulator of chromosome condensation, CHC1 protein, Elongation factor 2, Histone H3.1t, Prohibitin, isoform CRA_a, Prohibitin, Prohibitin variant, 60S ribosomal protein L24, Epididymis secretory protein Li 310, Ribosomal protein, large, P2, 60S acidic ribosomal protein P2, 40S ribosomal protein S10, 40S ribosomal protein S11, 40S ribosomal protein S13, 40S ribosomal protein S17, Ribosomal protein S23, isoform CRA_a, 40S ribosomal protein S23, 40S ribosomal protein S25, 40S ribosomal protein S4, 40S ribosomal protein S4, X isoform, 40S ribosomal protein S8, Ski oncogene (Proto-oncogene c-Ski), Sperm binding protein 1a, a protein encoded by cDNA FLJ38670 fis, clone HSYRA2000190, highly similar to Voltage-dependent anion-selective channel protein 1, Voltage-dependent anion-selective channel protein 1 (VDAC-1), Transcriptional repressor protein YY1, A-kinase anchor protein 9, Histone H1.3, Zinc finger C2HC domain-containing protein 1A, Prelamin-A/C, Lamin-B1, Alcohol dehydrogenase, Epididymis secretory protein Li 6, ATP5H protein, ATP synthase subunit d, mitochondrial, Myosin regulatory light chain 12A, Uncharacterized protein, Gag-Pro-Pol-Env protein, High mobility group protein HMG-I/HMG-Y, Cytochrome c oxidase subunit 4 isoform 1, mitochondrial, Tyrosine-protein kinase BAZ1B, Septin-9, 40S ribosomal protein S18, MCG23000, isoform CRA_b, Required for meiotic nuclear division protein 1 homolog, Heterogeneous nuclear ribonucleoprotein H3, Low-density lipoprotein receptor-related protein 1B, MICOS complex subunit MIC60, MICOS complex subunit, MICOS complex subunit MIC19, Rhomboid domain-containing protein 2, Armadillo repeat-containing X-linked protein 5, ATP-dependent RNA helicase DDX39A, Leucine-rich repeat-containing protein 31, Coiled-coil domain-containing protein 170, ABC50 protein, ATP-binding cassette sub-family F member 1, Cell division cycle 5-like protein, Myosin-10, 60S ribosomal protein L14, Sperm flagellar protein 2, Keratin, type II cytoskeletal 7, Similar to ribosomal protein L23, Gamma-tubulin complex component 6, Ribosomal protein L15, 60S ribosomal protein L15, KLHL20 protein, High mobility group nucleosome-binding domain-containing protein 5, Nucleolar protein 7, 60S ribosomal protein L10a, DNA-dependent protein kinase catalytic subunit, a protein encoded by cDNA FLJ51732, highly similar to Peroxisomal NADH pyrophosphatase NUDT12 (EC 3.6.1.22), Peroxisomal NADH pyrophosphatase NUDT12, 60S ribosomal protein L28, Heterogeneous nuclear ribonucleoproteins A2/B1, Serine/threonine-protein kinase SMG1, 40S ribosomal protein S9, Remodeling and spacing factor 1 (Rsf-1), Actin, cytoplasmic 1, BRCA1-A complex subunit RAP80, Galactose-3-O-sulfotransferase 3, 40S ribosomal protein S24, Bromodomain and WD repeat-containing protein 1, Junction plakoglobin, isoform CRA_a, Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1, 60S ribosomal protein L13, Phosphorylase b kinase regulatory subunit alpha, Heterogeneous nuclear ribonucleoprotein Q, Alsin, Synaptotagmin-like protein 1, Ribosomal protein L34, 60S ribosomal protein L34, Cingulin, Centromere protein T, Cingulin-like protein 1, Coiled-coil domain-containing protein 42, Heterogeneous nuclear ribonucleoprotein F, Mitochondrial import receptor subunit TOM40 homolog, FBL protein, ESF1 homolog, Calcium/calmodulin-dependent protein kinase type II subunit delta, 60S ribosomal protein L18, Protein Shroom3, Dynein heavy chain 5, axonemal, PC4 and SFRS1-interacting protein, Epididymis tissue sperm binding protein Li 14m, Trifunctional enzyme subunit alpha, mitochondrial, Bcl-2-like protein 12, Core histone macro-H2A.1, MTRF1 protein, Alstrom syndrome protein 1, UHRF1-binding protein 1-like, U5 small nuclear ribonucleoprotein 200 kDa helicase, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4, Transcription activator BRG1, Eukaryotic elongation factor 2 kinase, EVI5-like protein, Protein ECT2, CSC1-like protein 2, a protein encoded by cDNA FLJ35251 fis, clone PROST2003635, Nesprin-1, Nesprin-1, Chromodomain-helicase-DNA-binding protein 5, Midasin, Nesprin-2, Voltage-dependent anion-selective channel protein 3, ATPase family AAA domain-containing protein 5, N-alpha-acetyltransferase 15, NatA auxiliary subunit, Histone H2A type 2-B, Rootletin, Histone H2A, Histone H2A.J, PDZ domain-containing protein 8, Structural maintenance of chromosomes protein 1A, SMC1A protein, Vacuolar protein sorting-associated protein 13B, Centriolin, Pericentrin, Testicular secretory protein Li 14, Glutamate dehydrogenase 2, Myomesin-3, Acidic ribosomal phosphoprotein P1, Nucleolar protein 56, Nucleolar protein 58, Uncharacterized protein, FLJ00279 protein, a protein encoded by cDNA FLJ16045 fis, clone CTONG2000042, Probable C-mannosyltransferase DPY19L4, Coiled-coil domain-containing protein 18, FYVE, RhoGEF and PH domain-containing protein 6, ATP synthase subunit alpha, mitochondrial, Superkiller viralicidic activity 2-like 2, Phosphate carrier protein, mitochondrial, 40S ribosomal protein S6, EEF1D protein (Fragment), Sterile alpha motif domain-containing protein 9, Antigen MLAA-44, Coiled-coil and C2 domain-containing protein 1B, Elongation factor 1-gamma, Heterogeneous nuclear ribonucleoprotein U, Malignant fibrous histiocytoma-amplified sequence 1, Arachidonate 15-lipoxygenase, GC-rich sequence DNA-binding factor 2, 60S ribosomal protein L4, Regulator of G-protein signaling 20, Harmonin, Plectin, Kinesin-like protein KIF1B (Klp), Neuropilin-2, Neuropilin, Vacuolar protein sorting-associated protein 13D, Lymphoid-specific helicase, Histone H2B type 1-A, Ankyrin repeat domain-containing protein 11, Histone H2B (Fragment), Keratin, type II cytoskeletal 6A, Nipped-B-like protein (Delangin) (SCC2 homolog), ATPase family AAA domain-containing protein 1, Mitochondrial dynamin-like 120 kDa protein, Striated muscle preferentially expressed protein kinase, Disks large-associated protein 1, Dedicator of cytokinesis protein 11, Myomegalin, Putative uncharacterized protein DKFZp666F1010, Putative uncharacterized protein DKFZp666M0710, Putative uncharacterized protein DKFZp686P17171, Activation-dependent, raft-recruited ADAP-like phosphoprotein, Unconventional myosin-XVIIIa, Nucleolin, isoform CRA_b, Nucleolin, isoform CRA_c, Nucleolin (Protein C23), Keratin, type I cytoskeletal 9, Cilia-and flagella-associated protein 58, Terminal uridylyltransferase 4, WD repeat and SOCS box-containing protein 1, Centromere protein J, FRAS1-related extracellular matrix protein 1, Macoilin, NARGI protein (Fragment), Calpastatin isoform a variant (Fragment), Ribosomal protein L5 variant (Fragment), Insulin-like growth factor binding protein 2 variant (Fragment), Rho-associated protein kinase 2, 60S acidic ribosomal protein P0 (Fragment), Elongation factor 1-alpha (Fragment), Glial fibrillary acidic protein, Beta-actin-like protein 2, Fanconi anemia, complementation group D2, isoform CRA_b, Fanconi anemia group D2 protein, IQ and AAA domain-containing protein 1, Protein FAM92A, Teneurin-3, Coiled-coil and C2 domain-containing protein 2A, Putative uncharacterized protein C3orf49, Heterogeneous nuclear ribonucleoprotein A1, Dynein heavy chain 2, axonemal, Ribosomal protein (Fragment), RSLID1 protein (Fragment), ATP-dependent DNA helicase PIF1, Keratin, type II cytoskeletal 73, ATP synthase subunit beta, a protein encoded by cDNA FLJ39263 fis, clone OCBBF2009571, ATP-dependent RNA helicase A, Centrosomal protein of 290 kDa, CEP290 protein, Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1, La-related protein 7 , Pumilio homolog 3, Ovochymase-1, INO80 complex subunit, RWD domain-containing protein 3, Dual 3′, 5′-cyclic-AMP and -GMP phosphodiesterase 11A, Histone-lysine N-methyltransferase ASHIL, ATP-binding cassette sub-family C member 8, Cilia-and flagella-associated protein 157, M-phase phosphoprotein 1, isoform CRA_a, 60S ribosomal protein L3, A kinase (PRKA) anchor protein 6, isoform CRA_b, Lamin B2, isoform CRA_b, Nuclear mitotic apparatus protein 1, isoform CRA_a, Coiled-coil domain-containing protein 40, TBK1 binding protein 1, isoform CRA_a, Lamina-associated polypeptide 2, isoforms beta/gamma, KIAA1212, isoform CRA_a, Histone H2B, Septin 11, isoform CRA_b, Heterogeneous nuclear ribonucleoprotein A3, isoform CRA_a, MORC family CW-type zinc finger protein 4, Cytoplasmic dynein 2 heavy chain 1, Unconventional myosin-VIIb, Protein unc-13 homolog C, HSPA1L, Heat shock 70 kDa protein 1-like, Laminin subunit beta-4, Leucine-rich repeat-containing protein 43, Protocadherin Fat 3, Death-associated protein kinase, ADP/ATP translocase 2, SLC25A5 protein (Fragment), ADP/ATP translocase 3, SLC25A6 protein, HNRPR protein (Fragment), Poly [ADP-ribose] polymerase, Poly [ADP-ribose] polymerase 1, Protein AHNAK2, Myb-binding protein 1A, Leucine-rich repeat and IQ domain-containing protein 3, a protein encoded by cDNA FLJ76880, a protein encoded by cDNA FLJ76071, highly similar to Homo sapiens filamin A interacting protein 1 (FILIP1), mRNA, Structural maintenance of chromosomes protein, Coiled-coil domain-containing protein 180, Dynein heavy chain 17, axonemal, Histone H2A, a protein encoded by cDNA, FLJ95007, highly similar to Homo sapiens BRCA1 associated RING domain 1 (BARD1), mRNA, Protein fantom, Mpv17-like protein, Protein CASP, a protein encoded by cDNA FLJ44920 fis, clone BRAMY3011501, highly similar to Heterogeneous nuclear ribonucleoprotein U, ATPase family AAA domain-containing protein 3A, a protein encoded by cDNA FLJ35376 fis, clone SKMUS2004044, highly similar to Homo sapiens ribosomal protein L3 (RPL3), transcript variant 2, mRNA, SNF2LT, Dynein heavy chain 6, axonemal, Nuclear export mediator factor NEMF, a protein encoded by cDNA FLJ51361, highly similar to Keratin, type II cytoskeletal 6A, a protein encoded by cDNA FLJ57651, highly similar to Ketosamine-3-kinase, a protein encoded by cDNA FLJ50007, a protein encoded by cDNA FLJ52940, highly similar to Mortality factor 4-like protein 2, Protein RUFY3, Leucine-rich repeat and coiled-coil domain-containing protein 1, a protein encoded by CDNA FLJ60374, G-protein coupled receptor 176, a protein encoded by cDNA FLJ61500, highly similar to NNP-1 protein, Small nuclear ribonucleoprotein Sm D3, a protein encoded by cDNA FLJ54081, highly similar to Keratin, type II cytoskeletal 5, a protein encoded by cDNA FLJ58017, moderately similar to Treacle protein, Piwi-like protein 2, Serine/threonine-protein kinase N2, Dysferlin, Putative uncharacterized protein DKFZp469P0721, Short transient receptor potential channel 4, GTP-binding nuclear protein Ran, HNRNPL protein (Fragment), a protein encoded by cDNA FLJ52713, moderately similar to Mus musculus leucine rich repeat (in FLII) interacting protein 1 (Lrrfip1), mRNA, a protein encoded by cDNA FLJ50492, highly similar to Cyclin-dependent kinase-like 3 (EC 2.7.11.22), TBC1 domain family member 1, Non-POU domain-containing octamer-binding, 60S ribosomal protein L31, a protein encoded by CDNA FLJ51382, Protein Jumonji, von Willebrand factor A domain-containing protein 5B2, VWA5B2 protein (Fragment), Centrosomal protein of 128 kDa (Cep128), Proliferation marker protein Ki-67, Ribosomal protein L19, RPL27/NME2 fusion protein (Fragment), TPR and ankyrin repeat-containing protein 1, a protein encoded by cDNA FLJ90678 fis, clone PLACE1005736, highly similar to Pleckstrin homology domain-containing family A member 1, Pleckstrin homology domain-containing family A member 1, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5, Golgin subfamily B member 1, Heterogeneous nuclear ribonucleoprotein D-like, and combinations thereof.

3. The method of claim 1 , wherein said active agent is selected from geldanamycin, alvespimycin, entasobulin, androstanolone, spermine, cortisone, quercetin, acetohexamide, resveratrol, doxorubicin, ruxolitinib, roscovitine, sildenafil, teniposide, and combinations thereof.

4. The method of claim 1 , wherein said active agent is selected from roscovitine, geldanamycin, acetohexamide, ruxolitinib, and combinations thereof.

5. The method of claim 2 , wherein said one or more proteins that inhibit nucleic acid delivery vehicle uptake are selected from keratin 13, APC protein, protocadherin 17, spectrin alph (non-erythrocytic 1), and combinations thereof.

6. The method of claim 1 , wherein a period of time exists between step a and step b.

7. The method of claim 1 , wherein said nucleic acid is single stranded.

8. The method of claim 1 , wherein said nucleic acid is double stranded.

9. The method of claim 1 , wherein said method is carried out in vitro.

10. The method of claim 1 , wherein said method is carried out ex vivo.

11. A method of treating an individual, comprising

a. administering a compound selected from geldanamycin, alvespimycin, androstanolone, spermine, cortisone, quercetin, acetohexamide, resveratrol, doxorubicin, ruxolitinib, roscovitine, sildenafil, entasobulin, memantine, teniposide, etoposide, 3-aminobenzamide (INO 1001), diazoxide, tedisamil, glimepiride, epirubicin, annamycin, As 2 O 3 , (R/S)-repaglinide, 4β-aminoalkyl-4′-O-demethyl-4-desoxypodophyllotoxin (TOP53), acetohexamide, elasmitrucin, ketamine, NK109, tifenazoxide, olaparib, intoplicine, geldanamycin, alvespimycin, entasobulin, androstanolone/dihydrotestosterone, spermine, cortisone, quercetin, acetohexamide, resveratrol, doxorubicin, ruxolitinib, roscovitine/seliciclib, sildenafil, and teniposide/vumon to said individual; and

b. administering, to said individual, a nucleic acid nanoparticle comprising a polymer of lysine conjugated to polyethylene glycol (PEG) and complexed with a nucleic acid encoding a gene, or portion of a gene that encodes an active portion of a protein, that is expressed in said individual to provide a functional protein or functional protein fragment.

12. The method of claim 11 , wherein said compound is administered concurrently, before, or after administration of said nucleic acid nanoparticle.

13. The method of claim 11 , further comprising administering an RNAi that inhibits expression of a gene of claim 2 .

14. The method of claim 1 , wherein said method is carried out in vivo.

15. The method of claim 1 , wherein said nucleic acid is DNA.

16. The method of claim 1 , wherein said gene of interest encodes an active portion of a protein that can be expressed to provide a functional protein or protein fragment.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 23, 2024
From: CINCINNATI CHILDRENS HOSP MED CTR
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066211/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2022
From: ZIADY, ASSEM; SIEFERT, MATTHEW
To: CHILDREN'S HOSPITAL MEDICAL CENTER
Reel/Frame 058647/0996 →
Continuity (3)
Continuation 15690526 · Aug 30, 2017
Provisional Application 62381237 · Aug 30, 2016
Related Publication 20210102208A1 · Apr 8, 2021
References Cited (355)
US 4208479A · Zuk et al. · 1980 [cited by applicant]
US 7741038B2 · Sarwal et al. · 2010 [cited by applicant]
US 8017577B2 · Cooper et al. · 2011 [cited by applicant]
US 8911786B2 · Desai et al. · 2014 [cited by applicant]
US 9018179B2 · Kay et al. · 2015 [cited by applicant]
US 9993494B2 · Appleman et al. · 2018 [cited by applicant]
US 10126295B2 · Saavedra · 2018 [cited by applicant]
US 10300143B2 · Sengupta et al. · 2019 [cited by applicant]
US 10654910B2 · Spencer et al. · 2020 [cited by applicant]
US 10761099B2 · Ziady et al. · 2020 [cited by applicant]
US 10894960B2 · Ziady · 2021 [cited by examiner]
US 20060142225A1 · McSwiggen · 2006 [cited by applicant]
US 20060148828A1 · Gianella-Borradori et al. · 2006 [cited by applicant]
US 20060153808A1 · Cristofanilli et al. · 2006 [cited by applicant]
US 20060292562A1 · Pollard et al. · 2006 [cited by applicant]
US 20080133141A1 · Frost · 2008 [cited by applicant]
US 20120128782A1 · Green · 2012 [cited by examiner]
US 20130143752A1 · Edmiston et al. · 2013 [cited by applicant]
US 20170042819A1 · Goomer · 2017 [cited by applicant]
US 20170314074A1 · Kossen et al. · 2017 [cited by applicant]
US 20170360749A1 · Harijith et al. · 2017 [cited by applicant]
US 20180009873A1 · Spencer et al. · 2018 [cited by applicant]
US 20190128901A1 · Cozma · 2019 [cited by applicant]
US 20200341009A1 · Ziady et al. · 2020 [cited by applicant]
US 20220202902A1 · Ziady · 2022 [cited by applicant]
US 20230330121A1 · Ziady et al. · 2023 [cited by applicant]
US 20230416782A1 · Ziady et al. · 2023 [cited by applicant]
US 20240066021A1 · Ziady et al. · 2024 [cited by applicant]
US 20240103017A1 · Hardie et al. · 2024 [cited by applicant]
AU 2013270447A1 · 2014 [cited by applicant]
WO 2009038913A2 · 2009 [cited by applicant]
WO 2009055671A1 · 2009 [cited by applicant]
WO 2011038901A1 · 2011 [cited by applicant]
WO 2015157546A1 · 2015 [cited by applicant]
WO 2018208849A1 · 2018 [cited by applicant]
WO 2021053058A1 · 2021 [cited by applicant]
WO 2022031877A1 · 2022 [cited by applicant]
Brody, A.S., et al., “High-Resolution Computed Tomography in Young patients with Cystic Fibrosis: Distribution of Abnormalities and Correlation with Pulmonary Function Tests,” J Peds, 2004, 145(1):32-38, 7 pgs. [cited by applicant]
Chassagnon, G., et al., “Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor,” Eur Respir J, 2016, 48(1):249-252, 4 pgs. [cited by applicant]
Deboer, E.M., et al., “Proteomic profiling identifies novel circulating markers associated with bronchiectasis in cystic fibrosis,” Proteomics Clin Appl, 2017, 11(9-10):1600147, 9 pgs. [cited by applicant]
Deboer, E.M., et al., “Novel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid,” Proteomics Clin Appl, 2019, 13:1800085, 8 pgs. [cited by applicant]
Eichinger, M., et al., “Morphologic and functional scoring of cystic fibrosis lung disease using MRI,” European Journal of Radiology, 2012, 81(6):1321-1329, 9 pgs. [cited by applicant]
Fagerland, M.W., et al., “The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional,” BMC Med Res Methodol, 2013, 13:91, 8 pgs. [cited by applicant]
Guo, J., et al., “Longitudinal free-breathing MRI measurement of murine lung physiology in a progressive model of lung fibrosis,” J Appl Physio, 2019, 126(4):1138-1149, 12 pgs. [cited by applicant]
Hanania, N.A., et al., “Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial,” Respiratory Research, 2011, 12(1):6, 11 pgs. [cited by applicant]
Higano, N.S., et al., “Retrospective respiratory self-gating and removal of bulk motion in pulmonary UTE MRI of neonates and adults,” Magn Reason Med, 2017, 77(3):1284-1295, 25 pgs. [cited by applicant]
Higuchi, T., and V. Stella (Eds.), [cited by applicant]
Hoy, S.M., “Elexacaftor/Ivacaftor/Tezacaftor: First Approval,” Drugs, 2019, 79(18):2001-2007, 7 pgs. [cited by applicant]
King, T.E., et al., “A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis,” N Engl J Med, 2014, 370(22):2083-2092, 10 pgs. [cited by applicant]
Konstan, M.W., et al., “Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a … [cited by applicant]
Lederlin, M., et al., “Three-Dimensional Assessment of Lung Tissue Density Using a Clinical Ultrashort Echo Time at 3 Tesla: A Feasibility Study in Healthy Subjects,” J Magn Reson Imag, 2014, 40(4):839-847, 9 pgs. [cited by applicant]
Loew, W., et al., “A vol. Saddle Coil for Hyperpolarized 129Xe Lung Imaging,” Proc Int Soc Magn Reson Med, 2015, 23:1507, 1 pg. [Abstract only]. [cited by applicant]
Miller, G.W., et al., “Hyperpolarized [cited by applicant]
Niedbalski, P.J., et al., “Mapping and correcting hyperpolarized magnetization decay with radial keyhole imaging,” Magn Reson Med, 2019, 82:367-376, 10 pgs. [cited by applicant]
Pearce, M.S., et al., “Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study,” Lancet, 2012, 380(9840):499-505, 7 pgs. [cited by applicant]
Pipe, J.G., et al., “A New Design and Rationale for 3D Orthogonally Oversampled k-Space Trajectories,” Magn Reson Med, 2011, 66(5):1303-1311, 9 pgs. [cited by applicant]
Roach, D.J., et al., “Ultrashort Echo-Time Magnetic Resonance Imaging Is a Sensitive Method for the Evaluation of Early Cystic Fibrosis Lung Disease,” Ann Am Thorac Soc, 2016, 13(11):1923-1931, 9 pgs. [cited by applicant]
Robison, R.K., et al., “Three-Dimensional Ultrashort Echo-Time Imaging Using a FLORET Trajectory,” Magn Reson Med, 2017, 78(3):1038-1049, 12 pgs. [cited by applicant]
Roche, E.B., (Ed.), [cited by applicant]
Sawicki, G.S., et al., “Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data,” Am J Respir Crit Care Med, 2015, 192(7):836-842, 7 pgs. [cited by applicant]
Stanojevic, S., et al., “Physiologic endpoints for clinical studies for cystic fibrosis,” J Cyst Fibros, 2016, 15(4):416-423, 8 pgs. [cited by applicant]
Szczesniak, R.D., et al., “Dynamic predictive probabilities to monitor rapid cystic fibrosis disease progression,” Statistics in Medicine, 2020, 39(6):740-756, 17 pgs. [cited by applicant]
Szczesniak, R.D., et al., “Improving Detection of Rapid Cystic Fibrosis Disease Progression—Early Translation of a Predictive Algorithm Into a Point-of-Care Tool” IEEE Journal of Translational Engineering in Health and … [cited by applicant]
Szczesniak, R., et al., “Use of FEV1 in Cystic Fibrosis Epidemiologic Studies and Clinical Trials: A Statistical Perspective for the Clinical Researcher,” J Cyst Fibros, 2017, 16(3):318-326, 17 pgs. [cited by applicant]
Tepper, L.A., et al., “The development of bronchiectasis on chest computed tomography in children with cystic fibrosis: can pre-stages be identified?” Eur Radiol, 2016, 26(12):4563-4569, 7 pgs. [cited by applicant]
Thomen, R.P., et al., “Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients,” J Cyst Fibros, 2017, 16(2):275-282, 8 pgs. [cited by applicant]
Vestbo, J., et al., “Natural history of COPD: Focusing on change in FEV [cited by applicant]
Walkup, L.L., et al., “Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis,” Pediatr Radiol, 2016, 46(12):1651-1662, … [cited by applicant]
Walkup, L.L., et al., “Xenon-129 MRI detects ventilation deficits in pediatric stem-cell transplant patients unable to perform spirometry,” Eur Respir J, 2019, 53(5):1-16, 16 pgs. [cited by applicant]
Wielputz, M.O., et al., “Magnetic Resonance Imaging Detects Changes in Structure and Perfusion, and Response to Therapy in Early Cystic Fibrosis Lung Disease,” Am J Respir Crit Care Med, 2014, 189(8):956-965, 10 pgs. [cited by applicant]
Wilcoxon, F., “Individual Comparisons of Grouped Data by Ranking Methods,” Journal of Economic Entomology, 1946, 39(2):269-270, 2 pgs. [cited by applicant]
Willmering, M.M., et al., “Implementation of the FLORET Ultrashort Echo-Time Sequence for Lung Imaging,” Magn Reson Med, 2019, 82(3):1091-1100, 17 pgs. [cited by applicant]
Willmering, M.M., et al., “Improved pulmonary 129Xe ventilation imaging via 3D-spiral UTE MRI,” Magn Reson Med, 2020, 84(1):312-320, 14 pgs. [cited by applicant]
Yu, J., et al., “Comparison of Lung T [cited by applicant]
Zwart, N.R., et al., “Graphical Programming Interface: A Development Environment for MR1 Methods.,” Magn Reson Med, 2015, 74(5): 1449-1460, 12 pgs. [cited by applicant]
U.S. Appl. No. 17/333,058, filed May 28, 2021, by Ziady et al., entitled: “Compositions and Methods for Treatment of Lung Function.” [cited by applicant]
Accurso FJ, et al., “Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation.” N Engl J Med, Nov. 18, 2010, 363(21):1991-2003, 13 pgs. [cited by applicant]
Ahmed, H., et al., “Emerging Gene Therapies for Genetic Hearing Loss,” J Assoc Res Otolaryngol, Aug. 16, 2017, 22 pgs. [cited by applicant]
Albert PS, et al., “An Approach For Jointly Modeling Multivariate Longitudinal Measurements and Discrete Time-to-Event Data,” Ann Appl Stat, 2010, 4(3):1517-1532, 16 pgs. [cited by applicant]
Asar O, et al., “mmm: An R package for analyzing multivariate longitudinal data with multivariate marginal models,” Comput Methods Programs Biomed, 2013, 112(3):649-654, 6 pgs. [cited by applicant]
Brebner JA, et al., “Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?” F1000 Med Rep, 2013, 5:4, 6 pgs. [cited by applicant]
Bundgaard, H., (ed.), [cited by applicant]
Cai, X., et al., “Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa,” FASEB J, Apr. 2010, 24(4):1178-91, 25 pg… [cited by applicant]
Chatterjee N, et al., “Constrained Maximum Likelihood Estimation for Model Calibration Using Summary-level Information from External Big Data Sources” J Am Stat Assoc, 2016, 111(513):107-117, 11 pgs. [cited by applicant]
Chen J, et al., “Dysfunction of Nrf-2 in CF Epithelia Leads to Excess Intracellular H [cited by applicant]
Chen X, et al., “Nucleolin-Mediated Cellular Trafficking of DNA Nanoparticle Is Lipid Raft and Microtubule Dependent and Can Be Modulated by Glucocorticoid,” Mol Ther, 2011, 19(1):93-102, 10 pgs. [cited by applicant]
Chipman HA, et al., “BART: Bayesian Additive Regression Trees,” Ann Appl Stat, 2014, 23(1):42-59, 33 pgs. [cited by applicant]
Chirkova T, et al., “CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells,” J Gen Virol, 2015, 96:2543-2556, 14 pgs. [cited by applicant]
Chmiel J, et al., “The Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Glutathione, Markers of Oxidative Stress, and Neutrophil Migration,” Pediatr Pulmonol, 2012, 47(S35):250; 2012 Cystic Fibrosis Confer… [cited by applicant]
Chromy, B.A., et al., “Proteomic Analysis of Human Serum by Two-Dimensional Differential Gel Electrophoresis after Depletion of High-Abundant Proteins,” Journal of Proteome Research, 2004, 3:1120-1127, 8 pgs. [cited by applicant]
Chui, CK, et al., “Interpolation by Multivariate Splines,” Math Comput, 1988, 51(183):203-218, 16 pgs. [cited by applicant]
Clancy JP, et al., “Personalized Medicine in Cystic Fibrosis: Dawning of a New Era,” Am J Respir Crit Care Med, 2012, 186(7):593-597, 5 pgs. [cited by applicant]
Diggle PJ, et al., “Real-time monitoring of progression towards renal failure in primary care patients,” Biostatistics, 2015, 16(3):522-536, 15 pgs. [cited by applicant]
Ding, X.Q., et al., “Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina,” PLoS One, 2009, 4(10):e7410, 11 pgs. [cited by applicant]
Drumm ML, et al., “Genetic Variation and Clinical Heterogeneity in Cystic Fibrosis,” Annu Rev Pathol, 2012, 7:267-282, 18 pgs. [cited by applicant]
Duan LL, et al., “Joint Hierarchical Gaussian Process Model with Application to Forecast in Medical Monitoring,” 2014, eprint arXiv:1408.4660, 23 pgs. [cited by applicant]
Duan LL, et at., “Bayesian Ensemble Trees (BET) for Clustering and Prediction in Heterogeneous Data,” J Comput Graph Stat, 2016, 25(3):748-761, 14 pgs. [cited by applicant]
Farjo, R., et al., “Efficient non-viral ocular gene transfer with compacted DNA nanoparticles,” PLoS One, 2006, 1:e38, 12 pgs. [cited by applicant]
Feng, S., et al., “Recombinant adenoviral vector expressing human wild-type p53, GM-CSF, and B7-1 genes suppresses the growth of glioma in vivo,” Tumor Biol, 2014, 35:441-4417, 7 pgs. [cited by applicant]
Fieuws S, et al., “Predicting renal graft failure using multivariate longitudinal profiles,” Biostatistics, 2008, 9(3):419-431, 13 pgs. [cited by applicant]
Fieuws S, et al., “Random-effects models for multivariate repeated measures,” Stat Methods Med Res, Oct. 2007, 16(5):387-397, 11 pgs. [cited by applicant]
Fischer K, et al., “Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons,” PLoS Med, Feb. 2014, 11(2):e1001606, 12 pgs. [cited by applicant]
Fletcher, A.M., et al., “Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor,” Neuroscience, Oct. 27, 2011, 194:220… [cited by applicant]
Green, PJ, et al., “Nonparametric regression and generalized linear models: a roughness penalty approach,” 1 [cited by applicant]
Groot Kormelink, T., et al., “Immunoglobulin Free Light Chains Are Increased in Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis,” PLoS one, 2011, 6(9):e25392, 7 pgs. [cited by applicant]
Harun SN, et al., “A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis,” Paediatr Respir Rev, 2016, 20:55-66, 12 pgs. [cited by applicant]
Hastie T, et al., [cited by applicant]
Huang, J., et al., “CRISPR Editing in Biological and Biomedical Investigation,” J Cell Physiol, Aug. 8, 2017, 19 pgs. [cited by applicant]
Huang, L., et al., “Highly Selective Targeting of Hepatic Stellate Cells for Liver Fibrosis Treatment Using a D-Enantiomeric Peptide Ligand of Fn14 Identified by Mirror-Image mRNA Display,” Mol Pharmaceutics, 2017, 14:1… [cited by applicant]
James GM, et al., “Principal component models for sparse functional data,” Biometrika, 2000, 87(3):587-602, 16 pgs. [cited by applicant]
Jiang C-R, et al., “Covariate Adjusted Functional Principal Components Analysis for Longitudinal Data,” The Annals of Statistics, 2010, 38(2): 1194-1226, 34 pgs. [cited by applicant]
Kim PY, et al., “Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach,” J Proteomics, 2014, 96:1-12, 12 pgs. [cited by applicant]
Koirala, A., et al., “S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA,” Hum Mol Genet, Apr. 15, 2013, 22(8):1632-42, 11 pgs. [cited by applicant]
Kolodziej, M., et al., “Roscotirine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study,” Oncology Reports, 2015, 34:1549-1556, 8 pgs. [cited by applicant]
Konstan, M.W., et al., “Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution,” Hum.… [cited by applicant]
La Rosa PS, et al., “Hypothesis Testing and Power Calculations for Taxonomic- Based Human Microbiome Data,” PLoS One, 2012, 7(12):e52078, 13 pgs. [cited by applicant]
Laguna TA, et al., “Sputum Desmosine During Hospital Admission for Pulmonary Exacerbation in Cystic Fibrosis,” Chest, Dec. 2009, 136(6):1561-1568, 8 pgs. [cited by applicant]
Lancioni CL, et al., “ [cited by applicant]
Li Q, et al., “Rv2468c, a novel [cited by applicant]
Liou TG, et al., “Year-to-year changes in lung function in individuals with cystic fibrosis,” J Cyst Fibros, 2010, 9(4):250-6, 7 pgs. [cited by applicant]
Naso, M.F., et al., “Adeno-Associated Virus (AAV) as a Vector for Gene Therapy,” Bio Drugs, Jul.1, 2017, 31:317-334, 18 pgs. [cited by applicant]
Nick JA, et al., “Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis,” Thorax, 2013, 68(10):929-937, 9 pgs. [cited by applicant]
Obuchowski NA, et al., “Sample Size Determination for Diagnostic Accuracy Studies Involving Binormal ROC Curve Indices,” Stat Med, 1997, 16(13):1529-1542, 14 pgs. [cited by applicant]
Peila, C., et al., “Effects of Holder pasteurization on the protein profile of human milk,” Italian journal of Pediatrics, 2016, 42:36, 8 pgs. [cited by applicant]
Peng, J., Restricted MLE for Functional Principal Components Analysis (R package fpca) 2015. Available from: https://CRAN.R-project.org/package=fpca, 12 pgs. [cited by applicant]
Peng, J., et al., “A Geometric Approach to Maximum Likelihood Estimation of the Functional Principal Components From Sparse Longitudinal Data,” J Comput Graph Stat, 2009, 18(4):995-1015, Technical Report 2007a, 87 pgs. [cited by applicant]
Ramsay Jo, et al., Functional data analysis, Second Ed., Springer Science + Business Media, Inc., New York., NY, 2005, p. 426, (Table of Contents only) 13 pgs. [cited by applicant]
Ratjen F, et al., “Effect of Azithromycin on Systemic Markers of Inflammation in Patients With Cystic Fibrosis Uninfected With [cited by applicant]
Rosenfeld M, et al., “Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort,” Pediatr Pulmonol, 2010, 45(9):934-944, 11 pgs. [cited by applicant]
Rosenfeld M, et al., “Decline in Lung Function Does not Predict Future Decline in Lung Function in Cystic Fibrosis Patients,” Pediatr Pulmonol, 2015, 50(9):856-862, 7 pgs. [cited by applicant]
Sagel SD, et al., “Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation,” Ann Am Thorac Soc, 2015, 12(5):708-717, 10 pgs. [cited by applicant]
Sagel SD, et al., “Validation of Candidate Serum Protein and Lipid Markers of Disease Severity in CF,” Pediatr Pulmonol, 2014, 49(S38):288, 2014 Cystic Fibrosis Conference, Poster Session Abstract 205*, 1 pg. [cited by applicant]
Sanders DB, et al., “Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation,” Am J Respir Crit Care Med, 2010, 182(5):627-632, 6 pgs. [cited by applicant]
Schluchter MD, et al., “Classifying Severity of Cystic Fibrosis Lung Disease Using Longitudinal Pulmonary Function Data,” Am J Respir Crit Care Med, 2006, 174(7):780-786, 7 pgs. [cited by applicant]
Sinha C, et al., “Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry,” Chembiochem, 2015, 16:2017-2022, 6 pgs. [cited by applicant]
Sinha C, et al., “PKA and actin play critical roles as downstream effectors in MRP4-mediated regulation of fibroblast migration,” Cell Signal, 2015, 27(7):1345-1355, 11 pgs. [cited by applicant]
Slobodianik NH, et al., “Inflammatory biomarker profile in children with cystic fibrosis: preliminary study,” Proc Nutr Soc, 3rd International Immunonutrition Workshop; Session 4: Dietary strategies to prevent and mitig… [cited by applicant]
Sun, W., et al., “Real-Time Imaging of Gene Delivery and Expression with DNA Nanoparticle Technologies,” Chapter 33, In: Foote R., Lee J. (eds) Micro and Nano Technologies in Bioanalysis. Methods in Molecular Biology (M… [cited by applicant]
Szczesniak RD, et al., “A semiparametric approach to estimate rapid lung function decline in cystic fibrosis,” Annals of Epidemiology, 2013, 23(12):771-777, 7 pgs. [cited by applicant]
Szczesniak RD, et al., “Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood,” American Journal of Respiratory and Critical Care Medicine, 2017, 196(4): 471-478, 8 pgs. [cited by applicant]
Szczesniak RD, et al., “Predicting Future Lung Function Decline in Cystic Fibrosis Patients: Statistical Methods and Clinical Connections,” Pediatr Pulmonol, Letter to the Editor, 2016, 51(2):217-218, 2 pgs. [cited by applicant]
Tang Y, et al., “Developing Adaptive Personalized Therapy for Cystic Fibrosis Using Reinforcement Learning,” Submitted to Ann Appl Stat, 2012, 28 pgs. [cited by applicant]
Taylor-Robinson D, et al., “Understanding the natural progression in %FEV [cited by applicant]
Tibshirani RJ., “Regression Shrinkage and Selection via the Lasso,” J R Statist Soc B, 1996, 58(1):267-288, 22 pgs. [cited by applicant]
Tucholska M, et al., “Human Serum Proteins Fractionated by Preparative Partition Chromatography Prior to LC-ESI-MS/MS,” J Proteome Res, 2009, 8(3):1143-1155, 13 pgs. [cited by applicant]
Verbeke G, et al., “The analysis of multivariate longitudinal data: A review,” Stat Methods Med Res, 2014, 23(1):42-59, 18 pgs. [cited by applicant]
Wainwright CE, et al., “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” N Engl J Med, 2015, 373(3):220-231, 12 pgs. [cited by applicant]
Wang J, et al., “Measuring the impact of apnea and obesity on circadian activity patterns using functional linear modeling of actigraphy data,” J Circadian Rhythms, 2011, 9(1):11, 10 pgs. [cited by applicant]
Wang X, et al., “Hsp90 Cochaperone Ahal Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis,” Cell, 2006, 127(4):803-815, 13 pgs. [cited by applicant]
Wolff, M.E., (ed.), Burger's Medicinal Chemistry and Drug Discovery, 5th ed., 1995, pp. 172-178, 949-982, 41 pgs. [cited by applicant]
Xu, Z., et al. “Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest,” J Neurooncol, 2012, 108:59-67. [cited by applicant]
Yanagisawa K, et al., “Proteomic patterns of tumour subsets in non-small-cell lung cancer,” Lancet, 2003, 362(9382):433-439, 7 pgs. [cited by applicant]
Yao, F., et al., “Functional Data Analysis for Sparse Longitudinal Data,” Journal of the American Statistical Association, 2005, 100(470):577-590, 14 pgs. [cited by applicant]
Yurek, D.M., et al., “Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons,” Cell Transplant., 2009, 18(10):1183-96, 15 pgs. [cited by applicant]
Yurek, D.M., et al., “DNA Nanoparticles: Detection of Long-term Transgene Activity in Brain Using Bioluminescence Imaging,” Mol. Imaging, Apr. 26, 2011, 10(5):327-339, 12 pgs. [cited by applicant]
Yurek, D.M., et al., “Long-term transgene expression in the central nervous system using DNA nanoparticles,” Mol. Ther., Apr. 2009, 17(4):641-50, 14 pgs. [cited by applicant]
Zeitzer JM, et al., “Phenotyping Apathy in Individuals With Alzheimer Disease Using Functional Principal Component Analysis,” Am J Geriatr Psychiatry, 2013, 21(4):391-397, 12 pgs. [cited by applicant]
Zemanick ET, et al., “Inflammation and Airway Microbiota During Cystic Fibrosis Pulmonary Exacerbations,” PLoS One, 2013, 8(4):e62917, 13 pgs. [cited by applicant]
Zhang, X., et al., “CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy,” Sci. China Life Sci, May 2017, 60(5):468-75, 8 pgs. [cited by applicant]
Ziady AG, et al., “Interaction with CREB binding protein modulates the activities of Nrf2 and NF-κB in cystic fibrosis airway epithelial cells,” Am J Physiol Lung Cell Mol Physiol, 2012, 302(11):L1221-L1231, 11 pgs. [cited by applicant]
Ziady AG, et al., “Protein Sequencing with Tandem Mass Spectrometry,” Chapter 21, James Weifu Lee, et al., Eds. [cited by applicant]
Ziady AG, et al., “Proteomic Analyses of BALF Reveal Potential Biomarkers and Suggest Altered Lipid, Cyclic Nucleotide, and Iron Metabolism in Young CF Children Versus Disease Controls,” Pediatr Pulmonol, 2013, 48(S36):… [cited by applicant]
Ziady AG, et al., “Proteomic Analyses of Serum From CF Patients With Mild or Severe Disease Reveal the Differential Expression of Proteins That Regulate the Differentiation of Cartilage, Myeloid Leukocytes, and Intestin… [cited by applicant]
Ziady, A.G., et al., “Current prospects for gene therapy of cystic fibrosis,” Curr Opin Pharmacol, Oct. 2006, 6(5):515-21, 7 pgs. [cited by applicant]
Ziady, A.G., et al., “Functional evidence of CFTR gene transfer in nasal epithelium of cystic fibrosis mice in Vivo following luminal application of DNA complexes targeted to the serpin-enzyme complex receptor,” Mol. Th… [cited by applicant]
Ziady, A.G., et al., “Non-viral gene transfer therapy for cystic fibrosis,” Expert Opin Biol Ther, Jun. 2003, 3(3):449-58, 10 pgs. [cited by applicant]
International Search Report and Written Opinion dated Aug. 10, 2020 for Application No. PCT/US2020/030401, 10 pgs. [cited by applicant]
Altieri, D.C., “Validating Survivin as a Cancer Therapeutic Target,” Nat Rev Cancer, 2003, 3(1):46-54, 9 pgs. [cited by applicant]
Arai, H., et al., “Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas,” Brain Tumor Pathol, 2012, 29(3):160-167, 8 pgs. [cited by applicant]
Assi, H., et al., “Gene Therapy for Brain Tumors: Basic Developments and Clinical Implementation,” Neurosci Lett, 2012, 527(2):71-77, 14 pgs. [cited by applicant]
Bhang, H.-E.C., et al., “Tumor-Specific Imaging Through Progression Elevated Gene-3 Promoter-Driven Gene Expression,” Nat Med, 2011, 17(1):123-129, 16 pgs. [cited by applicant]
Bossen, C., et al., “Interactions of Tumor Necrosis Factor (TNF) and TNF Receptor Family Members in the Mouse and Human,” J Biol Chem, 2006, 281(20):13964-13971, 8 pgs. [cited by applicant]
Chen, X., et al., “Cell Surface Nucleolin Serves as Receptor for DNA Nanoparticles Composed of Pegylated Polylysine and DNA,” Mol Ther, 2008, 16(2):333-342, 10 pgs. [cited by applicant]
Christensen, C.L., et al., “Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay,” Clin Cancer Res, 2010, 16(8):2… [cited by applicant]
Dachs, G.U., et al., “From bench to bedside for gene-directed enzyme prodrug therapy of cancer,” Anti-Cancer Drugs, 2005, 16(4):349-359, 11 pgs. [cited by applicant]
Debinski, W., et al., “Convection-enhanced delivery for the treatment of brain tumors,” Expert Rev Neurother, 2009, 9(10):1519-1527, 15 pgs. [cited by applicant]
Fan, X., et al., “hTERT Gene Amplification and Increased mRNA Expression in Central Nervous System Embryonal Tumors,” Am J Pathol, 2003, 162(6):1763-1769, 7 pgs. [cited by applicant]
Fortin, S.P., et al., “Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Stimulation of Glioma Cell Survival Is Dependent Upon Akt2 Function,” Mol Cancer Res, 2009, 7(11):1871-1881, 24 pgs. [cited by applicant]
Galzio, R., et al., “Glycosilated Nucleolin as Marker for Human Gliomas,” J Cell Biochem, 2012, 113(2):571-579, 9 pgs. [cited by applicant]
Gurunathan, S., et al., “Regulation of Fibroblast Growth Factor-inducible 14 (Fn14) Expression Levels via Ligand-independent Lysosomal Degradation,” J Biol Chem, 2014, 289(19):12976-12988, 13 pgs. [cited by applicant]
Han, Z., et al., “AAV and Compacted DNA Nanoparticles for the Treatment of Retinal Disorders: Challenges and Future Prospects,” Invest Ophthalmol Vis Sci, 2011, 52(6):3051-3059, 9 pgs. [cited by applicant]
Haung, L., et al., “Highly Selective Targeting of Hepatic Stellate Cells for Liver Fibrosis Treatment Using a D-Enantiomeric Peptide Ligand of Fn14 Identified by Mirror-Image mRNA Display,” Mol Pharmaceutics, 2017, 14:1… [cited by applicant]
Hersh, D.S., et al., “The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance,” Neuro Oncol, 2018, 20(10):1321-1330, … [cited by applicant]
Jiang, X., et al., “The Imprinted Gene PEG3 Inhibits Wnt Signaling and Regulates Glioma Growth,” J Biol Chem, 2010, 285(11):8472-8480, 9 pgs. [cited by applicant]
Joo, K.M., et al., “Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ,” Cell Rep, 2013, 3(1):260-273, 14 pgs. [cited by applicant]
Kajiwara, Y., et al., “Expression of Survivin in Astrocytic Tumors: Correlation with Malignant Grade and Prognosis,” Cancer, 2003, 97(4):1077-1083, 7 pgs. [cited by applicant]
Kibbey, M.C., et al., “A 110-kD Nuclear Shuttling Protein, Nucleolin, Binds to the Neurite-Promoting IKVAV Site of Laminin-1,” J Neurosci Res, 1995, 42(3):314-322, 9 pgs. [cited by applicant]
Li, A., et al., “Unsupervised Analysis of Transcriptomic Profiles Reveals Six Glioma Subtypes,” Cancer Res, 2009, 69(5):2091-2099, 17 pgs. [cited by applicant]
Liu, G., et al., “Nanoparticles of Compacted DNA Transfect Postmitotic Cells,” J Biol Chem, 2003, 278(35):32578-32586, 9 pgs. [cited by applicant]
Martens, T., et al., “Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2,” Clin Ca… [cited by applicant]
Mastorakos, P., et al., “Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain,” Adv Healthc Mater, 2015, 4(7):1023-1033, 24 pgs. [cited by applicant]
Mead, B.P., et al., “Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model,” Nano Lett, 2017, 17(6):3533-3542, 21 pgs. [cited by applicant]
Nance, E.A., et al., “A Dense Poly(ethylene glycol) Coating Improves Penetration of Large Polymeric Nanoparticles within Brain Tissue,” Sci Transl Med, 2012, 4(149):149ra119, 18 pgs. [cited by applicant]
Ndesendo, V.M., “Convection-Enhanced Delivery of Neurotherapeutics,” In: V. Pillay and Y.E. Choonara, (Eds.), [cited by applicant]
Neeves, K.B., et al., “Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles,” Brain Res, 2007, 1180:121-132, 23 pgs. [cited by applicant]
Negroni, L., et al., “Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90B phosphorylation,” Mol Cancer Ther, 2007, 6(10)… [cited by applicant]
O'Mahony, A.M., et al., “Non-viral Nanosystems for Gene and Small Interfering RNA Delivery to the Central Nervous System: Formulating the Solution,” J Pharm Sci, 2013, 102(10):3469-3484, 16 pgs. [cited by applicant]
Ostrom, Q.T., et al., “CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010,” Neuro-Oncol, 2013, 15(Suppl 2):ii1-ii56, 56 pgs. [cited by applicant]
Patrizii, M., et al., “Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy,” Front Oncol, 2018, 8:article 23, 9 pgs. [cited by applicant]
Pelekanou, V., et al., “BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 Proteins Are Related to Human Glioma Tumor Grade: Immunohistochemistry and Public Microarray Data Meta-Analysis,” PLoS One, 2013, 8(12):e83250, 11 pgs. [cited by applicant]
Perez, J.G., et al., “The TWEAK Receptor Fn14 is a Potential Cell Surface Portal for Targeted Delivery of Glioblastoma Therapeutics,” Oncogene, 2016, 35(17):2145-2155, 27 pgs. [cited by applicant]
Phillips, H.S., et al., “Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis,” Cancer Cell, 2006, 9(3):157-173, 17 pgs. [cited by applicant]
Portsmouth, D., et al., “Suicide genes for cancer therapy,” Mol Aspects Med, 2007, 28(1):4-41, 38 pgs. [cited by applicant]
Redgate, E.S., et al., “Time of Death of CNS Tumor-Bearing Rats Can Be Reliably Predicted by Body Weight-Loss Patterns,” Lab Anim Sci, 1991, 41(3):269-273, 5 pgs. [cited by applicant]
Saucier-Sawyer, J.K., et al., “Distribution of Polymer Nanoparticles by Convection-Enhanced Delivery to Brain Tumors,” J Control Release, 2016, 232:103-112, 26 pgs. [cited by applicant]
Sausville, E.A. et al., “Contributions of Human Tumor Xenografts to Anticancer Drug Development,” Cancer Res, 2006, 66(7):3351-3354, discussion 3354, 4 pgs. [cited by applicant]
Schwartzbaum, J.A., et al., “Epidemiology and molecular pathology of glioma,” Nat Clin Pract Neurol, 2006, 2(9):494-503, 10 pgs. [cited by applicant]
Shirahata, M., et al., “Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis,” Clin Cancer Res, 2007, 13(24):7341-7356, 16 pgs. [cited by applicant]
Shirahata, M., et al., “Using gene expression profiling to identify a prognostic molecular spectrum in gliomas,” Cancer Sci, 2009, 100(1):165-172, 8 pgs. [cited by applicant]
Shirakawa, T., et al., “Cytotoxicity of Adenoviral-Mediated Cytosine Deaminase Plus 5-Fluorocytosine Gene Therapy is Superior to Thymidine Kinase Plus Acyclovir in a Human Renal Cell Carcinoma Model,” J Urol, 1999, 162(… [cited by applicant]
Soundararajan, S., et al., “Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells,” Mol Pharmacol, 2009, 76(5):984-991, 8 pgs. [cited by applicant]
Taillandier, L., et al., “Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice,” J Neurosci Methods, 2003, 125(1-2):147-157, 11 pgs. [cited by applicant]
Tobias, A., et al., “The art of gene therapy for glioma: a review of the challenging road to the bedside,” J Neurol Neurosurg Psychiatry, 2013, 84(2):213-222, 20 pgs. [cited by applicant]
Tran, N.L., et al., “Increased Fibroblast Growth Factor-Inducible 14 Expression Levels Promote Glioma Cell Invasion via Racl and Nuclear Factor-κB and Correlate with Poor Patient Outcome,” Cancer Res, 2006, 66(19):9535-… [cited by applicant]
Tran, N.L., et al., “The Human Fn14 Receptor Gene Is Up-Regulated in Migrating Glioma Cells in Vitro and Overexpressed in Advanced Glial Tumors,” Am J Pathol, 2003, 162(4):1313-1321, 9 pgs. [cited by applicant]
Trinh, Q.T., et al., “Enzyme/Prodrug Gene Therapy: Comparison of Cytosine Deaminase/5-Fluorocytosine Versus Thymidine Kinase/Ganciclovir Enzyme/Prodrug Systems in a Human Colorectal Carcinoma Cell Line,” Cancer Res, 199… [cited by applicant]
Vogelbaum, M.A. et al., “Convection-enhanced delivery for the treatment of glioblastoma,” Neuro-Oncol, 2015, 17(Suppl 2):ii3-ii8, 6 pgs. [cited by applicant]
Winkles, J.A., “The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting,” Nat Rev Drug Discov, 2008, 7(5):411-425, 32 pgs. [cited by applicant]
Workman, P., et al., “Guidelines for the welfare and use of animals in cancer research,” Br J Cancer, 2010, 102(11):1555-1577, 23 pgs. [cited by applicant]
Xu, Z., et al., “Orthotopic Patient-Derived Glioblastoma Xenografts in Mice,” Methods Mol Biol, Ch. 14 in Dimitris G. Placantonakis (ed.), [cited by applicant]
Yabroff, K.R., et al., “Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006,” Neuro-Oncol, 2012, 14(3):351-359, 9 pgs. [cited by applicant]
Yurek, D., et al., “Intracerebral injections of DNA nanoparticles encoding for a therapeutic gene provide partial neuroprotection in an animal model of neurodegeneration,” Nanomedicine: Nanotechnology, Biology, and Medi… [cited by applicant]
Yurek, D.M., et al., “Age and lesion-induced increases of GDNF transgene expression in brain following intracerebral injections of DNA nanoparticles,” Neuroscience, 2015, 284:500-512, 28 pgs. [cited by applicant]
Zarogoulidis, P., et al., “Suicide Gene Therapy for Cancer—Current Strategies,” J Genet Syndr Gene Ther, 2013, 4, 29 pgs. [cited by applicant]
Zhang, J., et al., “Gene-Directed Enzyme Prodrug Therapy,” Aaps J, 2015, 17(1):102-110, 9 pgs. [cited by applicant]
Zhou, H., et al., “Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC,” Mol Cancer Ther, 2014, 13(11):2688-2705, 34 pgs. [cited by applicant]
Ziady, A.-G., et al., “Minimal Toxicity of Stabilized Compacted DNA Nanoparticles in the Murine Lung,” Mol Ther, 2003, 8(6):948-956, 9 pgs. [cited by applicant]
Ziady, A.-G., et al., “Transfection of Airway Epithelium by Stable PEGylated Poly-L-lysine DNA Nanoparticles in Vivo,” Mol Ther, 2003, 8(6):936-947, 12 pgs. [cited by applicant]
European Search Report, Extended, and Written Opinion dated Dec. 14, 2021 for Application No. EP 21180569.2, 11 pgs. [cited by applicant]
Abedin, S., et al., “Predictive Value of Bronchiolitis Obliterans Syndrome Stage 0p in Chronic Graft-versus-Host Disease of the Lung,” Biol Blood Marrow Transplant, 2015, 21(6):1127-1131, 15 pgs. [cited by applicant]
Amanat, F., et al., “A serological assay to detect SARS-COV-2 seroconversion in humans,” Nat. Med, 2020, 26(7):1033-1036, 16 pgs. [cited by applicant]
Aurora, P., et al.,“Quality Control for Spirometry in Preschool Children with and without Lung Disease,” Am J Respir Crit Care Med, 2004, 169:1152-1159, 8 pgs. [cited by applicant]
Aziz, M.D., et al., “Disease Risk and GVHD Biomarkers Can Stratify Patients For Risk of Relapse and Non-Relapse Mortality Post Hematopoietic Cell Transplant,” Leukemia, 2020, 34(7):1898-1906, 17 pgs. [cited by applicant]
Benden, C., et al., “Therapy options for chronic lung allograft dysfunction-bronchiliolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review,” Jounral of Heart and Lung Transpla… [cited by applicant]
Bergeron, A., et al., “Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation,” Eur Respir J, 2018, 51:1702617, 13 pgs. [cited by applicant]
Brewington, J.J., et al., “Detection of CFTR function and modulation in primary human nasal cell spheroids,” J Cyst Fibros, 2018, 17(1):26-33, 17 pgs. [cited by applicant]
Callow, K.A., et al., “The time course of the immune response to experimental coronavirus infection of man,” Epidemiol Infect, 1990, 105:435-446, 12 pgs. [cited by applicant]
Casadevall, A., et al., “The convalescent sera option for containing COVID-19,” J Clin Invest, 2020, 130(4):1545-1548,. [cited by applicant]
Centers for Disease Control and Prevention (CDC) Revised U.S. surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases-United States and worldwide, Dec. 2003. MMWR Morb. Mortal.… [cited by applicant]
Chang, C.-K., et al., “Multiple Nucleic Acid Binding Sites and Intrinsic Disorder of Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein: Implications for Ribonucleocapsid Protein Packaging,” J Virol, 200… [cited by applicant]
Cheng, G.-S., et al., “Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant,” Ann Am Thorac Soc, 2016; 13(11):1932-1939, 8 pgs. [cited by applicant]
Chi, X., et al., “A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2,” Science, 2020, 369:650-655, 6 pgs. [cited by applicant]
Chien, J.W., et al., “Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease,” Biol Blood Marrow Transpl… [cited by applicant]
Cohen, H.Y., et al., “Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase,” Science, 2004, 305(5682):390-392. [cited by applicant]
Cox, D.R., et al., “Large Nos. of explanatory variables, a semi-descriptive analysis,” PNAS, 2017, 114(32):8592-8595, 4 pgs. [cited by applicant]
De Silva, T., et al., “Markers of rejection of a lung allograft: state of the art,” Biomark Med, 2022, 16(6):483-498, 16 pgs. [cited by applicant]
Deeks, J.J., et al. “Antibody tests for identification of current and past infection with SARS-CoV-2 (Review),” Cochrane Database Syst Rev, 2020, 6:CD013652, 306 pgs. [cited by applicant]
Dijkman, R., et al., “Human Coronavirus NL63 and 229E Seroconversion in Children,” J Clin Microbiol, 2008, 46(7):2368-2373, 6 pgs. [cited by applicant]
Du, L., et al., “The spike protein of SARS-CoV—a target for vaccine and therapeutic development,” Nat Rev Microbiol, 2009, 7:226-236, 11 pgs. [cited by applicant]
Dunn, M., et al., “Pediatric Bone Marrow Transplant Recipients That Develop Bronchiolitis Obliterans Syndrome Exhibit Significant Changes in Complement Activation, Angiotensin Maturation, and Cholesterol Processing Prio… [cited by applicant]
Eroshenko, N., et al., “Implications of antibody-dependent enhancement of infection for SARS-COV-2 countermeasures,” Nat Biotechnol, 2020, 38:789-791, 3 pgs. [cited by applicant]
Estenne, M., et al., “Bronchiolitis Obliterans Syndrome 2001: An Update of the Diagnostic Criteria,” J Heart Lung Transplant, 2002; 21:297-310, 14 pgs. [cited by applicant]
Fink, Z.W., et al., “PepSIRF: a flexible and comprehensive tool for the analysis of data from highly-multiplexed DNA-barcoded peptide assays,” arXiv, 2020, 5 pgs. [cited by applicant]
Fleri, W., et al., “The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design,” Front Immunol, 2017, 8:278, 16 pgs. [cited by applicant]
Friesen, R.H.E., et al., “A common solution to group 2 influenza virus neutralization,” PNAS, 2014, 111(1):445-450, 6 pgs. [cited by applicant]
Geyer, P.E., et al., “Plasma Proteome Profiling to Assess Human Health and Disease,” Cell Syst, 2016, 2:185-195, 12 pgs. [cited by applicant]
Geyer, P.E., et al., “Proteomics reveals the effects of sustained weight loss on the human plasma proteome,” Mol Syst Biol, 2016; 12:901, 16 pgs. [cited by applicant]
Gorse, G.J., et al., “Prevalence of Antibodies to Four Human Coronaviruses is Lower in Nasal Secretions than in Serum,” Clin Vaccine Immunol, 2010, 17(12):1875-1880, 6 pgs. [cited by applicant]
Gostic, K.M., et al., “Potent Protection against H5N1 and H7N9 Influenza via Childhood Hemagglutinin Imprinting,” Science, 2016, 354(6313):722-726, 16 pgs. [cited by applicant]
Grassi, N., et al., “Ultra-deep and quantitative saliva proteome reveals dynamics of the oral microbiome,” Genome Med, 2016, 8:44, 13 pgs. [cited by applicant]
Grifoni, A., et al., “Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,” Cell, 2020, 181:1489-1501, 29 pgs. [cited by applicant]
Halstead, S.B., et al., “Antibody-enhanced dengue virus infection in primate leukocytes,” Nature, 1977, 265:739-741, 3 pgs. [cited by applicant]
Hansen, J., et al., “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail,” Science, 2020, 369:1010-1014, 5 pgs. [cited by applicant]
Hartwell, M.J., et al., “An early-biomarker algorithm predicts lethal graft-versus-host disease and survival,” JCI Insight, 2017, 2(3):e89798, 9 pgs. [cited by applicant]
Hassan, J., et al., “Serum I [cited by applicant]
Heijerman, H.G.M., et al., “Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial,”… [cited by applicant]
Heltshe, S.L., et al., “Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement,” Am J Respir Crit Care Med, 2018, 197(11):1483-1486, 4 pgs. [cited by applicant]
Hildebrandt, G.C., et al., “Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus confrence on clinical practice in chronic GVHD,” Bone Marrow Transplant, 2011, 46(10):1283-1295, 13 pgs. [cited by applicant]
Hoofnagle, J.H., et al., “Antibody to Hepatitis B Core Antigen. A Sensitive Indicator of Hepatitis B Virus Replication,” N Engl J Med, 1974, 290:1336-1340, 5 pgs. [cited by applicant]
Huttenhain, R., et al., “A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer,” Mol Cell Proteomics, 2019, 18:1836-1850, 16 pgs. [cited by applicant]
Jagasia, M.H., et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report,” Biol Blo… [cited by applicant]
Jia, N., et al., “Emergence of human infection with Jingmen tick virus in China: A retrospective study,” EBioMedicine, 2019, 43:317-324, 8 pgs. [cited by applicant]
Jodele, S., et al., “Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab,” Blood, 2020, 135(13):1049-1057, 9 pgs. [cited by applicant]
Jodele, S., et al., “Interferon-complement loop in transplant-associated thrombotic microangiopathy,” Blood Adv, 2020, 4(6):1166-1177, 12 pgs. [cited by applicant]
Kall, L., et al., “Semi-supervised learning for peptide identification from shotgun proteomics datasets,” Nat Methods, 2007, 4(11):923-925, 3 pgs. [cited by applicant]
Katzelnick, L.C., et al., “Antibody-dependent enhancement of severe dengue disease in humans,” Science, 2017, 358:929-932, 4 pgs. [cited by applicant]
Keng, C.-T., et al., “Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agent… [cited by applicant]
Keogh, R.H., et al., “Dynamic Predication of Survival in Cystic Fibrosis: A Landmarking Analysis Using UK Patient Registry Data,” Epidemiology, 2019, 30(1):29-37, 9 pgs. [cited by applicant]
Khan, S., et al., “Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray,” bioRxiv, 2020, 10 pgs. [cited by applicant]
Khurana, S., et al., “Vaccine-Induced Anti-HA2 Antibodies Promote Virus Fusion and Enhance Influenza Virus Respiratory Disease,” Sci Transl Med, 2013, 5(200):200ra114, 10 pgs. [cited by applicant]
Konstan, M.W., et al., “Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis,” J Pediatr, 2007, 151(2):134-139e1, 7 pgs. [cited by applicant]
Konstan, M.W., et al., “Risk Factors For Rate of Decline in FEV [cited by applicant]
Kozlov, I.A., et al., “A Highly Scalable Peptide-Based Assay System for Proteomics,” PLoS One, 2012, 7(6):e37441, 10 pgs. [cited by applicant]
Krammer, F., et al., “Serology assays to manage COVID-19: Measurement of antibodies to SAR-CoV-2 will improve disease management if used correctly,” Science, 2020, 368(6495):1060-1061, 2 pgs. [cited by applicant]
Krisp, C., et al., “Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis,” Br J Cancer, 2018; 119:713-723, 11 pgs. [cited by applicant]
Ku, N-O., et al., “Mutation of Human Keratin 18 in Association with Cryptogenic Cirrhosis,” J Clin Invest, 1997, 99(1):19-23, 5 pgs. [cited by applicant]
Lai, S.-C., et al., “Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV),” J Biomed Sci, 2… [cited by applicant]
Larman, H.B., et al. “Application of a synthetic human proteome to autoantigen discovery through PhIP-Seq,” Nat Biotechnol, 2011, 29(6):535-541, 19 pgs. [cited by applicant]
Le, T.T., et al., “The COVID-19 vaccine development landscape,” Nat Rev Drug Discov, 2020, 19:305-306, 2 pgs. [cited by applicant]
Lederer, D.J., et al., “Control of Confounding and Reporting of Results in Casual Inference Studies: Guidance for Authors form Editors of Respiratory, Sleep, and Critical Care Journals,” Ann Am Thorac Soc, 2019, 16(1):2… [cited by applicant]
Li, D., et al., “Flexible semiparametric joint modeling: an application to estimate individual long function decline and risk of pulmonary exacerbations in cystic fibrosis,” Emerg Themes Epidemiol, 2017, 14:13, 13 pgs. [cited by applicant]
Liu, A., et al., “Antibody responses against SARS-CoV-2 in COVID-19 patients,” J Med Virol, 2021, 93:144-148, 5 pgs. [cited by applicant]
Liu, S., et al., “Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors,” Lancet, 2004, 363… [cited by applicant]
Liu, X., et al., “Proteomic Characterization Revels That MMP-3 Correlates With Bronchiolitits Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation,” Am J Transplant, 2016, 16(8):2342-2351… [cited by applicant]
Lounder, D.T., et al., “Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children,” Blood, 2017, 129(20):2801-2807, 7 pgs. [cited by applicant]
Lu, R., et al., “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding,” Lancet, 2020, 395:565-574, 10 pgs. [cited by applicant]
Lubroth, J., et al., “Absence of protein 2C from clarified foot-and-mouth disease virus vaccines provides the basis for distinguishing convalescent from vaccinated animals,” Vaccine, 1996, 14(5):419-427, 9 pgs. [cited by applicant]
Lucchese, G., et al., “Peptidology: short amino acid modules in cell biology and immunology,” Amino Acids, 2007, 33:703-707, 5 pgs. [cited by applicant]
Luebbering, N., et al., “Endothelial injury, F-actin and vitamin D binding protein after hematopoietic stem cell transplant and association with clinical outcomes,” Haematologica, 2021, 106(5):1321-1329, 9 pgs. [cited by applicant]
Lv, H., et al., “Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections,” Cell Rep, 2020, 31:107725, 10 pgs. [cited by applicant]
Magi, B. et al., “Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: A two-dimensional electrophoretic study,” Electrophoresis, 2002, 23:3434-3444, 11 pgs. [cited by applicant]
Major-Monfried, H., et al., “MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD,” Blood, 2018, 131(25):2846-2855, 10 pgs. [cited by applicant]
Middleton, P.G., et al., “Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele,” N Engl J Med, 2019, 381(19):1809-1819, 16 pgs. [cited by applicant]
Mina, M.J., et al., “Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens,” Science, 2019, 366(6465):599-606, 18 pgs. [cited by applicant]
Monto, A.S., et al., “The Doctrine of Original Antigenic Sin: Separating Good From Evil,” J Infect Dis, 2017, 215:1782-1788, 7 pgs. [cited by applicant]
Muhlebach, M.S, et al., “Biomarkers for Cystic Fibrosis Drug Development,” J Cyst Fibros, 2016, 15(6):714-723, 20 pgs. [cited by applicant]
Ni, L., et al., “Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals,” Immunity, 2020, 52:971-977, 11 pgs. [cited by applicant]
Nichols, D.P., et al., “The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease,” Am J Physiol Lung Cell Mol Physiol, 2009, 297(5):L828-L836, 9 pgs. [cited by applicant]
Nie, J., et al., “Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2,” Emerg Microbes Infect, 2020, 9:680-686, 7 pgs. [cited by applicant]
Pillay, T.S., “Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein,” J Clin Pathol, 2020, 73:366-369, 4 pgs. [cited by applicant]
Pinto, D., et al., “Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody,” Nature, 2020, 583:290-295, 22 pgs. [cited by applicant]
Poh, C.M., et al., “Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients,” Nat Commun, 2020, 11:2806, 7 pgs. [cited by applicant]
Price, J.V., et al., “‘On silico’ peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions,” Nat Med, 2012, 18(9):14341440, 16 pgs. [cited by applicant]
The R Core Team, “R: A Language and Environment for Statistical Computing, R Version 3.5.2” Vienna, Austria, R Foundation for Statistical Computing, 2018, https://www/R-project.org/, 3636 pgs. [cited by applicant]
Robbiani, D.F., et al., “Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals,” Nature, 2020, 584(7821):437-442, 35 pgs. [cited by applicant]
Routledge, E., et al., “Analysis of Murine Coronavirus Surface Glycoprotein Functions by Using Monoclonal Antibodies,” J Virol, 1991, 65(1):254-262, 9 pgs. [cited by applicant]
Rowe, S.M., et al., “Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis,” Am J Respir Crit Care Med, 2014, 190(2):175-184, 10 pgs. [cited by applicant]
Rubin, D.B., “Inference and Missing Data,” Biometrika, 1976, 63(3):581-592, 12 pgs. [cited by applicant]
Schaad, U.B., et al., “Serotype-Specific Serum I [cited by applicant]
Schluchter, M.D., et al., “Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients,” Stat Med, 2002, 21:1271-1287, 17 pgs. [cited by applicant]
Shiryaev, S.A., et al., “New Details of HCV NS3/4A Proteinase Functionality Revealed by a High-Throughput Cleavage Assay,” PLoS One, 2012, 7(4):e35759, 12 pgs. [cited by applicant]
Soares, H.D., et al., “Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease,” Arch Neurol, 2012, 69(10):1310-1317, 16 pgs. [cited by applicant]
Spivak, M., et al., “Improvements to the Percolator algorithm for peptide identification from shotgun proteomics data sets,” J Proteome Res, 2009, 8(7):3737-3745, 22 pgs. [cited by applicant]
Srinagesh, H.K., et al., “The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease,” Blood Advances, 2019, 3(23):4034-4042, 9 pgs. [cited by applicant]
Su, W., et al., “An empirical comparison of segmented and stochastic linear mixed effects models to estimate rapid disease progression in longitudinal biomarker studies,” Stat Biopharm Res, 2021, 13(3):270-279, 22 pgs. [cited by applicant]
Tamburro, R.F., et al., “Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation: A National Institutes of Health Workshop Summary,” Ann Am Thorac Soc, 2021, 18(3):381-394, 14 pgs. [cited by applicant]
Tan, C.W., et al., “A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction,” Nat Biotech, 2020, 38:1073-1078, 17 pgs. [cited by applicant]
Tissot, A., et al., “Early Identification of Chronic Lung Allograft Dysfunction: The Need of Biomarkers,” Frontiers in Immunology, 2019, 10:Article 1681, 13 pgs. [cited by applicant]
Uhlving, H.H., et al., “Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options,” Bone Marrow Transplantation, 2012, 47:1020-1029, 10 pgs. [cited by applicant]
Van Der Ploeg, E.A., et al., “The potenial of biomarkers of fibrosis in chronic lung allograft dysfunction,” Transplantation Reviews, 2021, 35(3):100626, 11 pgs. [cited by applicant]
Veraar, C., et al., “Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction,” Scientific Reports, 2021, 11(1):6799, 13 pgs. [cited by applicant]
Verhaeghe, C., et al., “Intrinsic pro-angiogenic status of cystic fibrosis airway epithelial cells,” BioChemical and Biophysical Research Communications, 2007, 356:745-749, 5 pgs. [cited by applicant]
Verleden, G.M., et al., “Azithromycin Reduces Airway Neutrophilia and Interleukin-8 in Patients with Brochiolitis Obliterans Syndrome,” Am J Respir Crit Care Med, 2006, 174:556-570, 5 pgs. [cited by applicant]
Verleden, S.E., et al., “Chronic lung allograft dysfunction phenotypes and treatment,” Journal of Thoracic Disease, 2017, 9(8):2650-2659, 11 pgs. [cited by applicant]
Volkova, N., et al., “Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries,” J Cystic Fibros, 2020, 19:68-79, 12 pgs. [cited by applicant]
Walls, A.C., et al., “Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion,” PNAS, 2017, 114(42):11157-11162, 6 pgs. [cited by applicant]
Waterhouse, A., et al., “SWISS-MODEL: homology modelling of protein structures and complexes,” Nucleic Acids Res, 2018, 46:W296-W303, 8 pgs. [cited by applicant]
Wewer Albrechtsen, N.J., et al., “Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery,” Cell Syst, 2018, 7:601-612.el-e3, 16 pgs. [cited by applicant]
Whitman, J.D., et al., “Test performance evaluation of SARS-CoV-2 serological assays,” Nat Biotechnol, 2020, 38(10):1174-1183, 26 pgs. [cited by applicant]
Wolff, D., et al., “Biomarkers in chronic graft-versus-host disease - quo vadis?” Bone Marrow Transplant, 2018, 53(7):832-837, 10 pgs. [cited by applicant]
Woolhouse, M.E.J., et al., “Epidemiological characteristics of human-infective RNA viruses,” Sci Data, 2018, 5:180017, 6 pgs. [cited by applicant]
Xia, S., et al., “A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike,” Sci Adv, 2019, 5:eaav4580, 15 pgs. [cited by applicant]
Xu, G.J., et al., “Comprehensive serological profiling of human populations using a synthetic human virome,” Science, 2015, 348(6239):aaa0698, 23 pgs. [cited by applicant]
Yu, J., et al., “Biomarker Panel for Chronic Graft-Versus-Host Disease,” J Clin Oncol, 2016, 34(22): 2583-2590, 10 pgs. [cited by applicant]
Yuan, M., et al., “A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV,” Science, 2020, 368:630-633, 4 pgs. [cited by applicant]
Zhu, N., et al., “A Novel Coronavirus from Patients with Pneumonia in China, 2019,” N Engl J Med, 2020, 382(8):727-733, 7 pgs. [cited by applicant]
Ziady, A.G., et al., “Redox balance in cystic fibrosis,” Int J Biochem Cell Biol, 2014, 0:113-123, 27 pgs. [cited by applicant]
Zost, S.J., et al., “Potently neutralizing and protective human antibodies against SARS-CoV-2,” Nature, 2020, 584(7821):443-449, 34 pgs. [cited by applicant]
European Search Report, Supplementary, and Written Opinion dated May 15, 2023, for Application No. EP 20798040.0, 9 pgs. [cited by applicant]
International Search Report and Written Opinion dated Dec. 30, 2021 for Application No. PCT/US2021/044587, 14 pgs. [cited by applicant]
International Search Report and Written Opinion dated Feb. 9, 2021 for Application No. PCT/US2020/054664, 12 pgs. [cited by applicant]
International Search Report and Written Opinion dated Mar. 28, 2022 for Application No. PCT/US2021/062624, 16 pgs. [cited by applicant]
International Search Report and Written Opinion dated Jun. 7, 2022 for Application No. PCT/US2022/012561, 21 pgs. [cited by applicant]
International Search Report and Written Opinion dated Sep. 25, 2023 for Application No. PCT/US2023/020341, 21 pgs. [cited by applicant]
International Search Report and Written Opinion dated Sep. 25, 2023 for Application No. PCT/US2023/020337, 22 pgs. [cited by applicant]